Scalped it on the long side a few times last week. Used the
Scalped it on the long side a few times last week. Used the support & resistance levels as guidelines & they played out nearly perfectly.
Holding some shares over the weekend hoping to see a break & hold above 1.75 followed by a break above the "mini" blue sky breakout above 1.88
If it breaks out above 1.88 it may just have the momo to push it up above 2.00
Have only done a little DD. Seems it's a "shell" that gains royalties from a number of drugs previously owned & now marketed by other companies. Some believe it to be a potential buyout target - if that's the case, one might want to look back at the price history. Found that pretty impressive.
I know Merck (ticker: MRK) markets one or more of the drugs ... they report earnings on 4/28. Those numbers may play a role in the price of ENZN moving forward in the short term.
I know one thing for sure from Friday - somebody was buying a boatload at the 1.65 price level.
Good luck!
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Capricor Under the Spotlight: FDA and SEC Concerns Ah, Capricor Therapeutics, Inc. (NASDAQ: CAPR)—a tale of high stakes and even higher expectations now hanging by a very taut thread. Investors are feeling the heat as the U.S. Food and Drug Administration (FDA) presses pause on Capricor's plans, and the courtroom drama unfolds with a securities class action looming over...
Continue Reading
La Rosa Holdings Reports Impressive Revenue Growth in 2024 Revenue for Q3 2024 Climbs 188% Year-Over-Year to $19.6 Million Aiming for $100 Million in Annualized Revenue by Year-End La Rosa Holdings Corp. (NASDAQ: LRHC) recently disclosed its financial progress, showcasing remarkable growth in the real estate sector. The company revealed that its total revenue witnessed a...
Continue Reading
Understanding Micron Technology's Market Landscape Investors have recently adopted a bearish stance towards Micron Technology (NASDAQ: MU), a trend that calls for attention among market participants. The sizable options activities we've noticed could hint at significant changes brewing in the market for this semiconductor giant. These insights stem from a comprehensive...
Continue Reading
Viz.ai is cutting through the noise in stroke treatment with its revolutionary technology. They’ve recently unveiled some pretty remarkable clinical data showcasing how their product, Viz LVO, can significantly alter the game for patients dealing with large vessel occlusions—an ischemic stroke that typically spells trouble. This isn’t just another tech story; it’s...
Continue Reading
Linda A. Smith Earned Pinnacle Professional Membership Linda A. Smith has made a remarkable mark in the finance sector, and her recent accolade as a Pinnacle Professional Member is a testament to her expertise and commitment. With more than 23 years of experience in finance and budgeting, she brings an impressive array of knowledge and skills to her role. Distinguished...
Continue Reading